Rationale for a trial of low-dose aspirin for the primary prevention of major adverse cardiovascular events and vascular dementia in the elderly: Aspirin in Reducing Events in the Elderly (ASPREE)

摘要: Low-dose aspirin (acetylsalicylic acid) therapy has been shown to reduce the risk of vascular events and there is increasing evidence its potential rate cognitive decline in elderly. Adverse effects including gastrointestinal intracranial haemorrhage may offset these benefits. The balance risks versus benefits for primary prevention cardiovascular disease dementia not established There clearly a need conduct study family practice investigate whether routine use low-dose elderly beneficial or harmful. Aspirin reducing (ASPREE) placebo-controlled trial major adverse dementia. It will follow 15 000 subjects aged 70 years more an average 5 years. This sample size power 87% detect 15% reduction group, with anticipated combined event 20 per 1000 patient